Trial Profile

A Randomized, Double-masked, Sham-controlled Phase 3b/4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy as Indicated in Subjects With Polypoidal Choroidal Vasculopathy

Status: Completed

Phase of Trial: Phase III/IV

Latest Information Update: 07 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary) ; Verteporfin
Indications Polypoidal choroidal vasculopathy; Wet age-related macular degeneration
Focus Therapeutic Use
Acronyms PLANET
Sponsors Bayer

14 Jan 2019 Status changed from active, no longer recruiting to completed.
30 Aug 2017 According to a Bayer media release, results from this trial will be presented at the European Society of Retina Specialists (EURETINA) Congress 2017.
23 Aug 2017 This trial has been completed in Germany (End date:07-07-2017).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com